234 related articles for article (PubMed ID: 30107273)
1. Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.
Wang P; Dong S; Zhao P; He X; Chen M
Biomaterials; 2018 Nov; 182():92-103. PubMed ID: 30107273
[TBL] [Abstract][Full Text] [Related]
2. Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.
Dong S; Wang P; Zhao P; Chen M
Mol Pharm; 2017 Oct; 14(10):3312-3321. PubMed ID: 28789525
[TBL] [Abstract][Full Text] [Related]
3. An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells.
Wang P; Zhao P; Dong S; Xu T; He X; Chen M
Theranostics; 2018; 8(1):223-236. PubMed ID: 29290804
[No Abstract] [Full Text] [Related]
4. Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.
Dong S; Xu T; Wang P; Zhao P; Chen M
Acta Pharmacol Sin; 2017 Jun; 38(6):914-923. PubMed ID: 28414197
[TBL] [Abstract][Full Text] [Related]
5. A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers.
Dong S; Xu T; Zhao P; Parent KN; Chen M
Theranostics; 2016; 6(5):666-78. PubMed ID: 27022414
[TBL] [Abstract][Full Text] [Related]
6. Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity.
Dong S; Subramanian S; Parent KN; Chen M
J Control Release; 2020 Dec; 328():653-664. PubMed ID: 32961248
[TBL] [Abstract][Full Text] [Related]
7. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
8. Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers.
Cho S; Dong S; Parent KN; Chen M
J Drug Target; 2016; 24(4):328-39. PubMed ID: 26307138
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
10. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
11. Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy.
Yu J; Wang S; Qi J; Yu Z; Xian Y; Liu W; Wang X; Liu C; Wei M
Int Immunopharmacol; 2021 Dec; 101(Pt A):108148. PubMed ID: 34653955
[TBL] [Abstract][Full Text] [Related]
12. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
13. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
14. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
Tang XD; Wang GZ; Guo J; Lü MH; Li C; Li N; Chao YL; Li CZ; Wu YY; Hu CJ; Fang DC; Yang SM
Mol Cancer Ther; 2012 May; 11(5):1183-92. PubMed ID: 22442309
[TBL] [Abstract][Full Text] [Related]
15. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.
Ossevoort MA; Feltkamp MC; van Veen KJ; Melief CJ; Kast WM
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):86-94. PubMed ID: 8574470
[TBL] [Abstract][Full Text] [Related]
17. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
Schnell S; Young JW; Houghton AN; Sadelain M
J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
Shibagaki N; Udey MC
J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
20. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
Li A; Xiong S; Lin Y; Liu R; Chu Y
DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
